ptizer inc east street new york, ny · ptizer inc 235 east 42nd street new york, ny 1ool7-5755...

Ptizer Inc 235 East 42nd Street New York NY 1OOl7-5755

March 252008

Steven Reynolds Director US Nuclear Regulatory Commission Division of Nuclear Material Safety 2443 Warrenville Road STE 2 10 Lisle IL 60532-4352

- Re Parent Company Guarantee for Pharmacia amp Upjohn Co (Kalamazoo MI)

Dear Mr Reynolds

I am the Chief Executive Officer of Pfizer Inc located at 235 East 42nd Street in New York NY 1001 7 This letter is in support of this firms use of the financial test to demonstrate financial assurance as specified in 10 CFR Part 30

I hereby certify that Pfizer Inc is currently a going concern and that it possesses positive tangible net worth in the amount of $23129000000

This firm is required to file a Form 10K with the US Securities and Exchange Commission for the latest fiscal year The fiscal year of this firm ends on December 3 1

I hereby certify that the content of this letter is true and correct to the best of my knowledge

ofthe ~ o a r d Chief Executive Officer

RECEIVED MAR 2 8 2008

Name of Facility

Pfizer Inr 235 East 42nd Street New lork NY 10007-5755

Certified Amount or Current Cost Estimates Location of Facility

March 25 2008

Pliarmacia amp Upjohn Company LLC License 2 1-00 182-03

Steven Reynolds Director U S N uc I ear Reg u la t ory C om m i ss i on Division of Nuclear Material Safet) 2443 Warrenville Road STE 2 I O Lisle IL 60532-4352

7000 Portage Road Kalamazoo MI 4900 1

- Re Financial Assurance for Pharmacia amp Upjohn Company LLC (Kalainazoo MI)

Dear Mr Reynolds

1 am the chief financial officer of Pfizer Inc 235 East 42Id Street New York Ne Yorh 1001 7 a corporation This letter is in support ofthis firms use of the parent coinpan guarantee financial test to demonstrate financial assurance as specified in I O CFR Part 30

This firm guarantees through the parent company guarantee submitted to demonstrate compliance under 10 CFR Part 30 the decoinmissioning of the following facilities owned or operated bq this firm The current cost estimates or certified amounts for decommissioning so guaranteed are s h o w for each fac i 1 i ty

$17133000

I hereby certify that Pfizer Inc is currently a going concern and that it possesses p0sitiLe tangible net worth i n the amount of $23129000000

The fiscal year ofthis f i rm ends on December 3 1 The figures for the foIIo~ing items niarhed vith a11 asterisk are derived from this firms independently audited year-end fliiancial statements and footnotes for the latest completed fiscal year ended December 3 I 2007 or from the firms internal accounting records underlying such financial statement A copy of this firms most recent financial statements is enclosed

This firm is required to file a Form IO-K with the US Securities and Exchange Commission for the latest fiscal year This firm has at least one class of equity securities registered under the Securities Exchange Act of 1934

1

Alternative 2

Current decommissioning cost estimates or certified amounts

a Decommissioning amounts covered by this parent $17133000 compaiiy guarantee

b All decommissioning amounts covered by other $39871 38 NRC or Agreement State parent company guarantees or self-guarantees

c All amounts covered bl parent company guarantees $l357 13646 self-guarantees or financial tests of other Federal or State agencies (eg EPA)

TOTAL $ I 56833784

Current bond rating of most recent unsecured issuance of this firm Senrice

Rating Name of Rating

A AAAa 1 Standard amp Poors and Moodys

Date of issuance of bond

Date of maturity of bond

051407 amp 121307

051517 amp 121514

2

3

4

5

6

7

8

9

I O

1 I

Tangible net worth (If any portion of estimates for decommissioning is included i n total liabilities on your firms financial statements you may add the amount of that portion to this line)

Total assets i n United States (required only if less than 90 percent of firms assets are located in the United States)

Is line 5 at least 10 times line I

Are at least 90 percent of firms assets located in the United States If not complete line 9

$23129000000

$295 12000000

YES NO X

X

Is line 6 at least I O times line I X

X

X

Is the rating specified on line 2 A or better

Does the licensee have at least one class of equity securities registered under the Securities Exchange Act of 1934

Represents identifiable assets only which includes net accounts ampr notes receivable inventories net fixed assets

2

I

goodwill and net intangibles


Effective Date March 25 2008

Pfizer Inc

Fa7 Jc2L-h Frank A DAmelio Senior Vice President and Chief Financial Officer

Signature of witness or notary Mamp

cc Dee L Clernent (Kalarnazoo MI)

3

KPMG LLP 345 Park Avenue NewYork NY 10154

Telephone 212 758 9700 Fax 212 758 9819 Internet wwwus kpmg corn

Independent Accountantsrsquo Special Report on Confirmation of Letter from Chief Financial Officer

The Board of Directors and Management of Pfizer Inc

We have audited the consolidated financial statements of Pfizer Inc (ldquothe Companyrdquo) for the year ended December 3 I 2007 and have issued our report thereon dated February 292008 Our work did not extend from the period of February 292008 through the date herein We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States) Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement As audit includes examining on a test basis evidence supporting the amounts and disclosures in the consolidated financial statements An audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluating the overall financial statement presentation The Company acquired Pharmacia Corporation on April 16 2003 Pharmacia amp Upjohn Company is a subsidiary of Pharmacia Corporation

Pfizer Inc has prepared documents to demonstrate its financial responsibility under the United States Nuclear Regulatory Commissionrsquos (ldquoNRCrdquo) financial assurance regulations 10 CFR Part 30 This letter is furnished to assist the following licensee in complying with these regulations and should not be used for other purposes

Pharmacia amp Upjohn Company 7000 Portage Road Kalamazoo MI 4900 1 License Nos 2 1-001 82-03

We have performed the procedures enumerated below which were agreed to by management of Pfizer Inc solely to assist management of the Company in complying with the NRC - Division of Waste Management financial assurance regulations Title 10 Chapter 1 of the Code of Federal Regulations part 30 (ldquo10 CFR part 30rdquo) Appendix C Criteria Relating to the Use of Financial Tests and Self Guarantees for Providing Reasonable Assurance of Funds for Decommissioning as of and for the year ended December 3 12007 Management of the Company is responsible for Pfizer Incrsquos compliance with those requirements This agreed-upon procedures engagement was conducted in accordance with attestation standards established by the American Institute of Certified Public Accountants The sufficiency of these procedures is solely the responsibility of management of the Company Consequently we make no representations regarding the

KPMG LLP a U S limited liability pannership I S the U S member firm of KPMG Internatmnal a Swiss cmperatlve

sufficiency of the procedures described below either for the purpose for which this report has been requested or for any other purpose

The attached schedule which was prepared by management of the Company reconciles the specified financial information furnished in the Company Chief Financial Officerrsquos (ldquoCFOrsquosrdquo) letter in response to the regulations with the Companyrsquos audited financial statements (ldquothe Letterrdquo) as of and for the year ended December 3 12007 In connection therewith we have

1 Compared the amounts in the column ldquoPer Financial Statementsrdquo to the amounts contained in the Companyrsquos audited financial statements for the year ended December 3 I 2007 and found them to be in agreement

2 Compared the amounts in the column ldquoPer CFOrsquos Letterrdquo to the amounts set forth in the Letter prepared in response to the NRCrsquos request and found them to be in agreement

3 Compared the amounts in the column ldquoReconciling Itemsrdquo to the amounts in the Companyrsquos Computron general ledger as of and for the year ended December 3 12007 and found them to be in agreement and

4 Recomputed the mathematical accuracy of the totals set forth in the attached schedule

We were not engaged to and did not conduct an examination the objective of which would be the expression of an opinion on the specified amounts in the Letter Accordingly we do not express such an opinion Had we performed additional procedures other matters might have come to our attention that would have been reported to you

This report is intended solely for the information and use of the Board of Directors and management of Pfizer Inc and is not intended to be and should not be used by anyone other than the Board of Directors and management of Pfizer Inc

March 252008

PFIZER INC Year Ended December 3 I 2007

Dollar amounts i n millions

Schedule of Reconciling Amounts Contained in Chief Financial Officerrsquos Letter with Amounts in Financial Statements

Line Number in CFOrsquos Letter

Per Per Financial Reconciling CFOrsquos Statements Items Letter

5 Total Shareholderrsquos Equity $65009 ($21382)

($20498)

Less Goodw i I I Less Identifiable intangible assets less accuin u I ated aiiiort izatio ri

Accrued decommissioning costs included in current liabilities

Tangible Net Worth

6

Total Identifiable Assets in the United States

$23129

Total Assets $ I 15268 Less Assets held outside the US Less Non-identifiable assets $6733 Effect of Corporate Consolidation Entries $ 7 3 19

($99809)

$293 I2

6

PARENT COMPANY GUARANTEE

Certified Amount or Name of Facility Location of Facility Current Cost Estimates

L

Pharmacia amp Upjohn 7000 Portage Road $17133000 Company LLC Kalamazoo MI 4900 1 License 2 1-00 182-03

Guarantee made this 25rsquordquo day of March 2008 by Pfizer Inc a corporation organized under the h s of the State of Delaware herein referred to as ldquoguarantorrdquo to the US Nuclear Regulatory Commission (NRC) beneficiary on behalf of our subsidiary Pliarmacia amp Upjohn Company LLC of 7000 Portage Road i n Kalarnazoo Michigan 4900 I

Recitals

1 The guarantor has full authority and capacity to enter into this guarantee under its bylaws articles of incorporation and the laws of the State of Delaware its State of incorporation Guarantor has approval from its Board of Directors to enter into this g uara t i tee

- 3 This guarantee is being issued to conipll vitli regulations issued bq the NRC an agency of the US Governnient pursuant to the Atomic Energy Act of 1954 as amended and the Energy Reorganization Act of 1974 NRC has promulgated regulations i n Title 10 Chapter I of tlie Code of Federal Regulations Part 30 which require that a holder of or an applicant for a materials license issued pursuant to 10 CFR Part 30 provide assurance that funds will be available when needed for required deco in in i ssio ni ng activities

3 The guarantee is issued to provide financial assurance for decornmissioning actiiities for the licensed facilities listed below as required by I O CFR Part 30 The decornmissioning costs for these activities are as follows

4 The guarantor meets or exceeds the following financial test criteria for commercial companies that issue bonds and agrees to comply with all notification requirements as specified i n I O CFR Part 30 and Appendix A to 10 CFR Part 30

The guarantor meets one of the following two financial tests

(a)(i) Two of the following three ratios a ratio of total liabilities to net ivorth less than 20 a ratio of the sum of net income plus depreciation depletion and

amortization to total liabilities greater than 01 and a ratio ofcurrent assets to current liabilities greater than 15 and

(a)(ii) Net working capital and tangible net worth each at least six times tlie costs covered by financial tests and

(a)(iii) Tangible net worth of at least $10 million and

(a)(iv) Assets located in tlie Uiiited States amouiiting to at least 90 percent of total assets or at least six times the costs covered by financial tests

OR

(b)(i) A current rating for its most recent bond issuance of AAA AA A or BBB as issued by Standard amp Poorrsquos or Aaa Aa A or Baa as issued by Moodylsquos and

(b)(ii) Tangible net worth at least six times the costs covered by financial tests and

(b)(iii) Tangible net worth of at least $10 million aiid

(b)(iv) Assets located i n the Uiiited States amounting to at least 90 percent of total assets or at least six times the costs covered by financial tests

The guarantor has majority control of the voting stock for the following licensees covered by this guarantee

5

Name of Facility

Pharmacia amp Upjolin Company LLC License 2 1-00 I 82-03


7000 Portage Road $17133000 Kalamazoo MI 49001

I

6 Decommissioning activities as used below refer to the activities required by 10 CFR Part 30 for decommissioning of the facilities identified above

7 For value received from Pharmacia and Upjohn Company and pursuant to the guarantorrsquos authority to enter into this guarantee the guarantor guarantees to tlie NRC that if the licensee fails to perform the required decommissioning activities as required by License Nos 24-01 113-03 and 24-01 1 13-24 the guarantor shall

(a) carry out the required decotninissioning activities

(b) set u p a trust fund in favor of the above identified beneficiary in the amount of the current cost estimates for these activities

8 The guarantor agrees to submit revised financial statements financial test data and an auditorrsquos special report and reconciling schedule annually within 90 days of the close of its fiscal year

9 The guarantor agrees that if at the end of any fiscal year before termination of this guarantee it fails to meet the financial test criteria the licensee shall send within 90 days of the end of the fiscal year by certified mail notice to the NRC that the licensee intends to provide alternative financial assurance as specified in 10 CFR Part 30 Within I20 days of such notice the guarantor shall establish such firiaricial assurance if Pharmacia aiid Upjohn Company has not done so

2

I O

1 1

12

13

14

16

17

The guarantor also agrees to notify the beneficiary promptly if tlie ownership of the licensee or the parent firm is transferred and to maintain this guarantee until the new parent firm or tlie licensee provides alternative financial assurance acceptable to the beneficiary

The guarantor agrees that if it determines at any time other than as described i n Recital 9 that it no longer meets the financial test criteria or it is disallowed from continuing as a guarantor it shall establish alternative financial assurance as specified in I O CFR Part 30 40 70 or 72 as applicable within 30 days in the name of Pharmacia and Upjohn Company unless Pharinacia and Upjohn Company has done so

The guarantor as well as its successors and assigns agrees to remain bound jointly and severally under this guarantee notwithstanding any or all of the following amendment or modification of tlie license or NRC-approved decommissioning funding plan for that facility the extension or reduction of the time of performance of required activities or any other modification or alteration of an obligation of the licensee pursuant to 10 CFR Part 30

The guarantor agrees that all bound parties shall be jointly and severally liable for all litigation costs incurred by the beneficiarj NRC i n any successful effort to enforce the agreement against the guarantor

Tlie guarantor agrees to remain bound under this guarantee for as long as Pharniacia and Upjohn Company must comply with the applicable financial assurance requirements of 10 CFR Part 30 for tlie previously listed facilities except that the guarantor may cancel this self-guarantee by sending notice by certified mail to tlie NRC such cancellation to become effective no earlier than 120 days after receipt of such notice by the NRC as evidenced by tlie return receipt

Tlie guarantor agrees that if Pharinacia and Upjohn Company fails to provide alternative financial assurance as specified i n I O CFR Part 30 and obtain written approval of such assurance from the NRC within 90 days after a notice of cancellation by the guarantor is received by both the NRC and Pharinacia and Upjohn Company from the guarantor tlie guarantor shall provide such alternative financial assurance i n tlie name of Pharinacia and Upjohn Company or make full payment under tlie self- guarantee

Tlie guarantor espresslq waives notice of acceptance of this guarantee by the NRC or by Pharmacia and Upjohn Company The guarantor also expressly waives notice of ani en din en t s or in od i fica t ion s of the dec o in in i ss ion i n g req u i re ni e ti t s and of ani en dm en t s or modifications of tlie license

If the guarantor files financial reports with the US Securities and Escliange Coinmission then it shall promptly submit them to its independent auditor and to tlie NRC during each year i n which this guarantee is in effect

3

1 hereby certify that this guarantee is true and correct to the best of my knowledge

EffectiLe date March 25 2008

Pfizer Inc

FA 3rsquo9LQ- Frank A DrsquoAmelio Senior Vice President and Chief Financial Officer

Signature of Lvitness or notary wKbvamp

4

KPMG LLP 345 Park Avenue New York NY 10154

Telephone 212 758 9700 Fax 212 758 9819 Internet wwwuskpmg corn

Independent Accountantsrsquo Report on Applying Agreed-Upon Procedures


We have performed the procedures enumerated below which were agreed to by management of Pfizer Inc (ldquothe Companyrdquo) solely to assist management of the Company in evaluating Pfizer Incrsquos letter (attached) to the United States Nuclear Regulatory Commission (ldquoNRCrdquo) regarding the Companyrsquos use of financial tests to demonstrate financial assurance as specified in the NRC - Division of Waste Management financial assurance regulations Title 10 Chapter 1 of the Code of Federal Regulations Part 30 (rdquo10 CFR part 30rdquo) Appendix C Criteria Relating to the Use of Financial Tests and Serf Guarantees for Providing Reasonable Assurance of Funds for Decommissioning as of and for the year ended December 3 1 2007 Management of Pfizer Inc is responsible for the Companyrsquos compliance with those requirements This agreed-upon procedures engagement was conducted in accordance with attestation standards established by the American Institute of Certified Public Accountants The sufficiency of these procedures is solely the responsibility of management of the Company Consequently we make no representation regarding the sufficiency of the procedures described below either for the purpose for which this report has been requested or for any other purpose

The procedures and associated findings are as follows

1 We obtained a copy of the letter from the Companyrsquos Senior Vice President and Chief Financial Officer Frank DrsquoAmelio to the NRC (the ldquoLetterrdquo) which includes one of the two financial tests specified in Appendix C to 10 CFR part 30 related to the Kalamazoo MI facility defined in the Letter

2 We recalculated the tangible net worth of Pfizer Inc in the amount of $23129 million as presented in the Letter utilizing amounts included in the December 31 2007 audited consolidated financial statements and footnotes of the Company or specifically total shareholdersrsquo equity minus goodwill and minus identifiable intangible assets less accumulated amortization all of which were as of December 3 1 2007 and found them to be in agreement

3 We recalculated the dollar amount of total assets in the United States in the amount of $29512 million as presented in the Letter utilizing amounts included in the Companyrsquos accounting records as of December 31 2007 specifically the summation of the identifiable assets which includes accounts and notes receivable - net inventories fixed assets - net goodwill and identifiable intangible assets less accumulated amortization as reported in the Companyrsquos Hyperion Financial Management system balance sheet as of December 3 12007 and found them to be in agreement

KPMG LLP a U S limited liability partnership is the U S member firm of KPMG lnlernalional a Swiss cwperative

4 We verified the Companyrsquos assertion as presented in the Letter that it is not true that at least 90 percent of the Companyrsquos assets at December 3 1 2007 are located in the United States by dividing the dollar amount of total assets in the United States in the Letter (and recalculated by us in Procedure 3 above) by the amount of the Companyrsquos total assets included in the December 3 1 2007 audited consolidated financial statements without except ion

5 We obtained a schedule reconciling the amounts contained in the Letter with amounts in the Companyrsquos consolidated financial statements as of and for the year ended December 3 I 2007 (the ldquoSchedulerdquo) which will be attached to the Accountantsrsquo Special Report on Confirmation of Letter from Chief Financial Officer In connection with the Schedule we

a Compared the amounts in the column ldquoPer Financial Statementsrdquo to the amounts contained in the Companyrsquos audited consolidated financial statements for the year ended December 3 I 2007 and found them to be in agreement

b Compared the amounts in the column ldquoPer CFOrsquos Letterrdquo to the amounts set forth in the Letter prepared in response to the NRCrsquos request and found them to be in agreement

c Compared the amounts in the column ldquoReconciling Itemsrdquo to the amounts in the Companyrsquos Computron general ledger as of and for the year ended December 3 1 2007 and found them to be in agreement and

d Recomputed the mathematical accuracy of the totals set forth in the Schedule

6 We obtained a draft copy of the letter from the Companyrsquos Chairman and Chief Executive Officer Jeffrey B Kindler Esq to the NRC (the ldquoCEOrsquos Letterrdquo) which related to the Parent Company Guarantee for Pharmacia Corporation (Kalamazoo MI) as defined in the CEOrsquos Letter

7 We recalculated the tangible net worth of Pfizer Inc at December 3 I 2007 as described in Procedure 2 above and compared it to tangible net worth of Pfizer Inc at December 3 12007 as presented in the CEOrsquos Letter and found them to be in agreement

We were not engaged to and did not conduct an examination the objective of which would be the expression of an opinion on the specified amounts in the letter Accordingly we do not express such an opinion Had we performed additional procedures other matters might have come to our attention that would have been reported to you

This report is intended solely for the information and use of the Board of Directors and management at Pfizer Inc and is not intended to be and should not be used by anyone other than the Board of Directors and management of Pfizer Inc

March 25 2008

Report of Independent Registered Public Accounting Firm on the Consolidated Financial Statements

The Board of Directors and Shareholders of Pfizer Inc

We have audited the accompanying consolidated balance sheets of Pfizer Inc and Subsidiary Companies as of December 31 2007 and 2006 and the related consolidated statements of income shareholders equity and cash flows for each of the years in the threeyear period ended December 31 2007 These consolidated financial statements are the responsibility of the Companys management Our responsibility is to express an opinion on these consolidated financial statements based on our audits

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States) Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement An audit includes examining on a test basis evidence supporting the amounts and disclosures in the financial statements An audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluatinq the overall financial statement presentation We believe that our audits provide a reasonable basis for our opinion

In our opinion the consolidated financial rtatements referred to above present fairly in all material respects the financial position of Pfizer Inc and Subsidiary Companies as of December 31 2007 and 2006 and the results o f their operations and their cash flows for each of the years in the three-year period ended December 31 2007 in conformity with US generally accepted accounting principles

We also have audited in accordance with the standards of the Public Company Accounting Oversight Board (United Statps) t he effectiveness of Pfizer Inc and Subsidiary Companies internal control over financial reporting as of December 31 2007 based on criteria established in Internal ControClntegrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and our report dated February 29 2008 expressed an unqualified opinion on the effective operation of the Companys internal control over financial reporting

As discussed in the Notes t o the Consolidated Financial Statements-Wote ID Significant Accounting Policies New Accounring Standards effective January 12007 Pfizer Inc adopted the provisions o f Financial Accounting Standards Board lnrerpretation (FASB) No 48 Accounting for Uncertainty in tniome Tdxes an interpretation o f SFAS U9 Accounting for income Taxes and supplemented by FASB Financial Staff Position FIN 48-1 D e f h t i o n of Settlement in FASB Interpret3ton No 47 issued May 2 2007

As discussed in the Notes t o the Consolidated Financial Statemenls-Note ID Significant Accounting Policies New Accountmg Standards effective January 12006 Pfizer Inc adopted the provampons of Statement of FindnChl Accounting Standards No 123R Share-Based Payment

As discussed in the Notes t o the Consolidated Financial Statements-Note ID Significdnt Accounbng Policies New Accounting Standards effective December 31 2006 Pfizer Inc adopted the provisions of Statement of Financial 4ccounting St lards No 158 Employers Accounting for Defined Benefit Pension and Other Postretirement Plans (an ~ m e n d m e n t of Financial Accounting Standards Board Statements No 87 88 106 and 132R)

As discussed in the Notes t o the Consolidated Financial Statements-Note ID Significant Accountrng Polkces New Accounting Standards effective December 31 2005 Pfizer Inc adopted he provisions of Financial Accounting Standards Board (FASB) Interpretation No 47 (FIN 47) Accounting for Conditional 4sser Retirement Obliptions (an interpretation of FASB Statement No 143)

KPMC LLP New York New York

February 29 2008

2007 F i r a n m i Rewr i 37

Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting


We have audited the internal control over financial reporting of Pfizer Inc and Sbbsidiary Companies as of December 31 2007 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) Pfizer Inc and Subsidiary Companies management is responsible for maintaining effective internal control over financial reporting and for i t s assessment of the effectiveness of internal control over financial reporting included in the accompanying Managements Report on Internal Control Over Financial Reporting Our responsibility is t o express an opinion on the Companys internal control over financial reporting based on our audit

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States) Those standards require that we plan and perform the audit t o obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects Our audit included obtaining an understanding of internal control over financial reporting assessing the risk that a material weakness exists testing and evaluating the design and operating effectiveness of internal control based on risk assessment Our audit also included performing such other procedures as we considered necessary in the circumstances We believe that our audit provides 3 reasonable basis for our opinion

A companys internal control over financial reporting i s a process designed to provide reasonable assurance regarding the reliability of financial reportinq and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles A companys internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial

Statements in accordance with generally accepted accounting principles and that receipts and expenditures of the company are being made only in accordance w i th authorizations o f management and directors of the company and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the companys assets that could have a material effect on the financial statements

Because of i t s inherent limitations internal control over financial reporting may not prevent or detect misstatements Also projections of any evaluation of effectiveness to future periods are subject t o the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate

In our opinion Pfizer Inc and Subsidiary Companies maintained in all material respects effective internal control over financial reporting as of December 31 2007 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)

We also have audited in accordance with the standards of the Public Company Accounting Oversight Board (United States) the consolidated balance sheets of Pfizer Inc and Subsidiary Companies as of December 312007 and 2006 and the related consolidated statements of income shareholders equity and cash flows for each of the years in the three-year period ended December 31 2007 and our report dated February 29 2008 expressed an unqualified opinion on those consolidated financial statements

KPMG LLP New York New York

February 292008

38 1007 rinancidl RPDOR

-- ConLerted by SEC Publisher created by BCL I echnologies I I K I b r SEC Filing

EX-2 1 12 c52 104-ex2 1 htm

of 15

EXHIBIT 21

SUBSIDIARIES OF T H E COMPANY

The following is a list of subsidiaries of the Company as of December 3 I 2007 omitting some subsidiaries which considered in the aggregate would not constitute a significant subsidiary

N A M E Where Incorporated 4 I2357 Ontario Inc Canada A S Ruffel (Mozambique) Limitada AS Ruffel (Private) Limited A i 0 Pfizer Russia Adenylchemie GtnbH Germany Agouron Pharmaceuticals Inc California Alginate Industries (Ireland) Ltd Ireland American Food Industries Inc Delaware Andean Services SA Colombia A ngiosy ti I tic Delaware Balverda SRL Italy BINESA 2002 SL Spain Biocor Animal Health Inc Delaware Bioindustria Farmaceutici SRL Italy Bioren Inc Delaware BioRexis Pharmaceutical Corporation Delaware Biosearch Manufacturing Sr1 Italy Blue Whale Re Ltd Venn on t CP Irsquoharniaceuticals International CV Netherlands Capsugel (Thailand) Co Ltd Thailand Capsugel Belgium BVBA Belgium Capsugel de Mexico S de RL de CV Mexico Capsugel France France Capsugel Healthcare Limited lndia Capsugel Japan Inc ( K K ) Japan Capsugel Ploennel France CARDEL France Cen trofarma Sociedad Anon i ma Guatemala Ceuticlab Laboratorios de Produtos Farmaceuticos Lda Portugal Charlie Papa Operations LLC New Jersey CHC Direct LLC Delaware Compania Farmaceutica Upjohn SA Guatemala Consumer Health Products (Minority Interests) Companyunited Kingdom Continental Farmaceutica SL Spain Continental Pharma Inc Delaware Davis Medica Sociedad Limitada Sociedad Unipersonal Spain Distribuidora Mercantil Centro Americana SA Delaware Duchem Laboratories Li in ited lndia Einbres Bio-Tech Trade (Shanghai) Co Ltd Peoplersquos Republic of China Einbres De Mexico S de RL de CV Mexico Embrex Europe Limited United Kingdom

Mozambique Zi in babwe

1~ttpw~wsecgovArchivesedgardat~7800300009304 130800 1360c52 104-ex2 1 htm 312 1 ZOO8

-

-- Cornrerted by SEC Publisher created b j BCL lechiiologies Inc for SEC Filing

Embres France Embres lberica s1 Embres Poultry Health LLC Embres Sales Inc Embres Inc Esperion LUV Development Inc Esperion Therapeutics Inc Farniinova Produtos Farniaceuticos de Inovacao Lda Farmitalia Carlo Erba Limited

France Spain North Carolina North Carolina North Carolina Delaware Delaware Portugal United Kingdom

Page 2 of 15

1it tpl ~~~~usecgoviArchivesedgardat~7800300009~04 1 30800 1360c52 104 - ex2 1 litin 312 12008

-- Converted by SEC Publisher creatccl 1 3 ~ I3CL I cchnologies Inc frsquoor S I X Filing Page 3 of 15

Farniogene Productos Fartnaceuticos Lda G D Searle amp Co Limited G D Searle (Thailand) Limited G D Searle International Capital LLC G D Searle LLC G D Searle South Africa (Pty) Ltd Godecke GmbH Godecke OTC Beteiligungs GmbH Greenstone LLC Hepar Contribution LLC Idun Pharmaceuticals Inc lnovoject do Brasil Liinitada International Affiliated Corporation LLC Invicta Farina SA J B Tillott Limited Jouveinal Holland BV Kenfarina SA Keys ton e Chemurgic Corporation Kiinteisto oy Espoon Pellavaniementie 14 Kiinteisto Oy Helsingin Tietokuja Kommanditbolaget Hus Gron Korea Pharrna Holding Company Limited Laboratoires Pfizer S A Laboratorios Laprofa Sociedad Anonima Laboratorios Parke Davis SL Laboratorios Pfizer Ltda Laboratorios Pfizer Lda Lothian Developments V SPRL MED Urological Inc Mederio AG Meridica Limited Monterey Kelp Corporation MTG Divestitures Handels GtnbH MTG Divestitures Limited MTG Divestitures LLC Nefox Farma SA Nostrum Farma SA OCT (Thailand) Ltd Orsim PanServ Personalberatungs- und Anzeigens Paris Montrouge I I (Nederland) BV Paris Montrouge I I SARL Parke Davis 8 Co Limited Parke Davis International Limited Parke Davis Productos Farmaceuticos Lda Parke Davis Pty Limited Parke Davis amp Company Limited Parke Davis amp Company LLC Parke-Davis GmbH Parke-Davis Manufacturing Corp Parke-Davis Sales Corporation

Portugal United Kingdom Thailand Delaware Delaware South Africa Germany German) Delaware Delaware Delaware Brazil Delaware Spain United Kingdom Netherlands Spain Delaware Finland Finland Sweden Hong Kong Morocco Guatemala Spain Brazil Portugal Belgium Minnesota Switzerland United Kingdom Ca I i forti ia Austria United Kingdom Delaware Spain Spain Thailand France

erv ice G m b H Germ any Netherlands France Isle of Jersey Bahamas Portugal Australia Pakistan Michigan G enn any Delaware Virgin Islands

littpll~~li~secgovArchivesedgardata7800300009304 130800 1360c52 104-ex2 1 htm 32 12008

-- Converted by SEC Publisher created by BCL lsquoIlsquocchnologies Inc for SEC Filing

P-D Co Inc Delaware Pfidev3 (SAS) France Pfidev4 (SAS) France Pfizer (China) Research and Development Co Ltd Pfizer (Malaysia) Sdn Bhd Malaysia Pfizer (Perth) Pt Limited Australia Pfizer (SAS) France

Peoplersquos Republic of China

Page 4 of 15

1~t tp ~rsquo~~i rsquo ~ec g0~Archi~e~edgar da ta i7800300009~04 1 30800 1360c52 104-ex2 1 htm 32 112008

-- Conwted b SIltC fublisher created b) I3CL Technologies Inc lor SEC Filing

Pfizer (Thailand) Limited Thailand Ptizer AG Switzerland Ptizer A S Norway Pfizer A B Sweden Pfizer Africa amp Middle East for Pharmaceuticals Animal Health amp

Egypt Pfizer Afrique de LOuest Senegal Pfizer Algerie Sante et Nutrition Animale spa Algeria Pfizer Animal Health BV Netherlands Pfizer Animal Health Korea Ltd South Korea Pfizer Animal Health MA EElG United Kingdom Pfizer Animal Health SA Belgium Pfizer ApS Denmark Ptizer Asia Contract Operations Pte Ltd Singapore Pfizer Asia Holdings BV Netherlands Pfizer Asia Manufacturing PTE Ltd Singapore Pfizer Asia Pacific Pte Ltd Singapore Pfizer Australia Holdings Pty Limited Australia Ptizer Australia Pty Limited Australia Pfizer Australia Superannuation Pty Ltd Australia Pfizer BV Netherlands Ptizer Berlin GtnbH G erni any Pfizer Betei ligungs-G tii b H Germany Pfizer Bolivia SA Bolivia Pfizer Canada Inc Canada Pfizer Caribe Limited Guernsey Pfizer Chile SA Chile Pfizer Cia Ltda Ecuador Pfizer Consumer Inc Japan Pfizer Continental Holdings SARL Luxembourg Pfizer Continental Services LLC Delaware Ptizer Convention I l l LLC Delaware Ptizer Convention IV LLC Delaware Pfizer Co-Promotions Limited Pfizer Cork Limited Ireland Ptizer Corporation Panama Pfizer Corporation Austria Gesellschaft mbH Austria Pfizer Corporation Hong Kong Limited Hong Kong Ptizer Croatia do0 Croatia P fizer Deutsch land G ni bH Germany Ptizer Distribution Company Ireland P fi ze r D i s t r i bu t i o ti Services Be Ig i u i n

Ptizer Domestic Ventures Limited Isle of Jersey P tizer Dorn i ti icana S A Doin in ican Republic

Pfizer Enterprises Inc Delaware Pfizer Enterprises SARL Luxembourg Pfizer ESP Pty Ltd Australia Pfizer Europe Holdings SARL Luxembourg Ptizer Europe MA EElG Pfizer Europe Services LLC Delaware

C h em icals S A E

Isle of Jersey

Pfizer Egypt SAE Egypt

United Kingdom

Page 5 of 15

1ittpwuu~secgovArchivesedgardat~7800300009304 130800 1360~52 104-ex2 1 htm 312 1 no08

~ -__~

-- Converted by SEC Publisher created by BCL lsquoIrsquoechnologies Inc fbr SEC Filing

Ptizer European Service Center BVBA Pfizer Export AB Pfizer Export Company Pfizer Finance GmbH amp Co KG Pfizer Finance International Pfizer Finance Share Service (Dalian) Co Ltd Pfizer Finance Vertvaltungs GmbH

Belgium Sweden I re Ian d Germany Ireland PeopJersquos Republic of China Germany

Page 6 of 15

h t tp l l~~~~~~ se~ gov Arc1 i i~~es edga r da t~78003 00009~04 1 30800 1360c52 1 04 - ex2 1 htm 32 1 12008

Pfizer Financial Services N V S A Pfizer Fundings International Pfizer Global Holdings BV Pfizer Global Investmetits SARL Pfizer Global Supply Pfizer Global Trading Pfizer GmbH Ptizer Group Limited Pfizer HCP Corporation Ptizer Health AB Pfizer Health Solutions Inc Pfizer Healthcare Consultant (Shanghai) Co Ltd Ptizer Healthcare Ireland Pfizer Hellas AE Ptizer HK Service Company Limited Pfizer Holding France (SCA) Pfizer Holding Italy SpA Pfizer Holding und Verwaltungs GmbH Pfizer Holding Ventures Pfizer Holdings BV Pfizer Holdings Bermuda Ltd Pfizer Holdings Europe

Be Ig ium Ireland Netherlands Luxembourg Ireland Ireland Germany United Kingdom New York Sweden Delaware Peoplersquos Republic of China Ireland Greece Hong Korig France Italy Germany Ireland Netherlands Bermuda Ireland

- -

-- c O I I I crtcd b SI C rsquo Irsquoublisher created b) 13CL rsquolrsquoeclinologies Inc for SEC Filing

Pfizer Holdings International Luxembourg (PHIL) Sarl Luxembourg Pfizer Holdings Luxembourg SARL Ptizer Holdings Mexico S de RL de CV Pfizer Holdings Netherlands BV Pfizer Holdings Turkey Limited Pfizer Hitngaq Asset Management LLC Pfizer llaclari Limited Sirketi Pfizer International Bank Europe Pfizer International Corporation P tizer I tit erna t ional H o I d i ngs Pfizer International LLC P fize r I titer ti at iona I LU s e m bou rg SA Pfizer International Operations (S A S) Pfizer International Trading (Shanghai) Limited Pfizer Inventory Co Pfizer Investment Capital Pfizer Investment Co Ltd Pfizer Ireland Pharmaceuticals Pfizer Ireland Pharinaceuticals Ptizer Ireland Ventures Pfizer ltalia Sr1 Pfizer Japan Inc Pfizer Jersey Capital Limited Pfizer Jersey Company Limited Pfizer Jersey Finance Limited Pfizir Laboratories (Pty) Limited Ptizer Laboratories Limited Ptizer Laboratories Limited Pfizer Litnitada

Luxetn bourg Mexico Netherlands Isle of Jersey Hungary Turkey Ireland Panama I re I and New York Luxembourg France Peoplersquos Republic of China Delaware Ireland Peoplersquos Republic of China Ireland Ireland Ireland Italy Japan Isle of Jersey Isle of Jersey Isle of Jersey South Africa Kenya Pakistan Angola

Page 7 of 15

1i t tp ~~~~~secgovArchivesedgardat~7800~00009304 130800 1360c52 104-ex2 1 htm 3212008

-- Converted by SEC Publisher created b HCL Icchnologies Inc for SEC Filing

Ptizer Limited Pfizer Limited Pfizer Limited Pfizer Limited Pfizer Limited Pfizer LLC Pfizer Lusco Holdings Sad

Taiwan Tanzania Thailand Uganda United Kingdom Russia Luxembourg

Page 8 of 15

httpw~~~~secgovArchivesedgardata7800300009304130800 1360c52104-ex2 1 htm 32 12008

-- ConLertcd 17) SI-ltrsquo Irsquoiit7lishcr crcatcil 12) K l lsquoI ethnologies Inc for SEC Filing Page 9 of 15

Pfizer Lusco Production SARL Luxetn bourg Pfizer Luxembourg SARL Luxembourg Pfizer Manufacturing Belgium NV Belgium Pfizer Manufacturing Deutschland GmbH Gennany Pfizer Manufacturing Frankfurt GtnbH Germany Ptizer Manufacturing Frankfurt Verwaltungs GtnbH Germany Pfizer Manufacturing LLC Delaware P fizer Manufacturing Services Ireland Pfizer Medical Technology Group (Belgium) NV Pfizer Middle East for Pharmaceuticals Animal Health and

Belgium

Chemicals SA E Pfizer Namibia (Proprietary) Limited Pfizer New Zealand Limited Pfizer OTC BV Pfizer OTC Beteiligungs GmbH Pfizer Overseas LLC Ptizer Oy Pfizer Participations SARL Pfizer Pension Trustees (Ireland) Limited Pfizer Pension Trustees Ltd Ptizer PGM (SAS) Pfizer PGRD (SAS) Ptizer Phartn Algerie Ptizer Pharma GtnbH Pfizer Pharnia Trade LLC Ptizer Pharmaceutical (Wuxi) Co Ltd Pfizer Pharmaceutical India Pvt Ltd Pfizer Pharmaceutical Trading Limited Liability

Company ( a W a Pfizer Kft or Pfizer LLC) Ptizer Pharmaceuticals BV Pfizer Pharmaceuticals Israel Ltd Ptizer Pharmaceuticals Jersey Limited Pfizer Pharmaceuticals Korea Limited Pfizer Pharniaceuticals Limited Pfizer Pharmaceuticals LLC P fize r Pharmaceutic a I s L t d Pfizer Pharmaceuticals Tunisie Sarl Pfizer Pigments Inc Pfizer Polska Sp ZOO

Pfizer Precision Holdings SARL Ptizer Prev - Sociedade de Previdencia Privada Pfizer Private Limited Ptizer Private Ltd Ptizer Production LLC Ptizer Products Inc Pfizer Products India Private Limited Pfizer Romania SRL Pfizer SA Pfizer SA Pfizer SGPS Lda Pfizer SRL

Egypt Namibia New Zealand Netherlands Germany Delaware Finland Luxembourg Ireland United Kingdom France France Algeria Germany

Peoplersquos Republic of China India

Egypt

Hungary Netherlands Israel Isle of Jersey South Korea Cayman Islands Delaware Peoplersquos Republic of China Tunisia Delaware Poland Luxembourg Brazil Ma lays i a Singapore Delaware Connecticut India Romania Co tom b i a Peru Portugal Argentina

httpwwwsecgovArchivesed~ardata7800300009304 130800 1 360c52 104-ex2 1 htm 312 1 ZOO8

-- Converted by SEC Publisher created by BCL Technologics Inc 1i)r SEC Filing

Pfizer SA (Belgium) Belgium Pfizer Saidal Manufacturing Algeria Pfizer Science and Technology Ireland Limited Ireland Pfizer Service Company BVBA Belgium Pfizer Service Company Ireland Ireland Pfizer Services I (SNC) France Pfizer Services 2 (SNC) France

Page 10 of 15

httpuuwsecgovArchivesedgardata7800300009304 1308001360c52104 - ex21 httn 312 112008

-- Converted bq SLClsquo Irsquoublisher created b 13CL lsquollsquoechnologies Inc fix SEC Filing Page 1 1 of 15

Pfizer Services LLC Ptizer Shared Services Pfizer Shareholdings Intermediate SARL Pfizer Singapore Trading Pte Ltd Pfizer Specialities Ghana Ptizer Specialties Limited Pfizer Sterling Investments Limited Pfizer Suzhou Animal Health Products Co Ltd Pfizer Suzhou Pharmaceutical Co Ltd Pfizer Technologies Limited Pfizer Trading Polska spz00 Pfizer Tunisie SA Ptyzer UK Group Limited Pfizer Vaccines LLC Pfizer Venezuela SA Ptizer Ventures Limited Ptizer Warner Lambert Luxembourg SARL Pfizer Zona Franca SA Pfizer Inc Pfizer SA Pfizer SA Ptizer SA de CV Ptizer spol s ro Pharniacia amp Upjohn Cambridge Limited Pharmacia amp Upjohn Company LLC Pharmacia ampr Upjohn Company Inc Phamiacia ampr Upjohn Holding Cornpan) Pharmacia amp Upjohn LLC

Delaware Ireland Luxembourg Singapore Ghana Nigeria Isle of Jersey Peoplersquos Republic of China Peoplelsquos Republic of China United Kingdom Poland Tunisia United Kingdom Delaware Venezuela Isle of Jerse Luxembourg Costa Rica Philippines Costa Rica Spain Mexico Czech Republic United Kingdom Delaware Delaware Delaware Delaware

Phamiacia amp Upjohn Management Company Limited United Kingdom Pharmacia amp Upjohn SpA Italy Pharniacia amp Upjohn Trading Corporation Michigan Pharmacia amp Upjohn SA de CV Mexico Pharmacia (South Africa) (Pty) Ltd South Africa Phamiacia Africa Ltd United Kingdom Phamiacia Animal Health Limited United Kingdom Pharmacia Asia Limited Hong Kong Pharmacia Australia Pt) Ltd Australia Pharmacia BV Netherlands Pharniacia Brasil Ltda Brazil Pharinacia Corporation Delaware Phartiiacia de Centroamerica SA Panama Phamiacia de Mexico SA de CV Mexico Phamiacia Diagnostics Venvaltungs GmbH Gennany Pharmacia Europe EEIG United Kingdom Pharniac ia Gin bH Germany Pharmacia Grupo Pfizer SL Spain Pharmacia Hepar Inc Delaware Pharmacia Holding AB Sweden Pharmacia [lac Sanayi ve Ticaret Limited Sirketi Turkey Pharmacia Inter-American LLC Michigan Phartnacia International BV Netherlands

littp~~~~~secgovArchivesedgardata7800300009304 130800 1 360c52 1 04-ex2 1 htm 32 12008

Pharmacia International Inc South Dakota Pharmacia International SARL Switzerland Pharmacia Ireland Limited Ireland Phamiacia Korea Ltd South Korea Pharinacia Laboratories Limited United Kingdom Pharinacia Learning Center Corporation Delaware Pharmacia Limited United Kingdom

Page 12 of 15

httpwww sec govArchivesedgardata78003000093 04 1 30800 1 3 60c52 1 04-ex2 1 htm 32 1 L O O 8

-- Converted by SEC Publisher crcated b 13C1 Irsquocclinologies Inc Ibr SEC Filing

Pharinacia Limited Company Pharniacia Little Island Limited Phannacia Malaysia Sdn Bhd P harm ac ia Pharmatrade L LC Pharmacia Polska Spz00 Pharmacia SA Phannacia Searle Limited Phartnacia Singapore Pte Ltd Pharinacia UK Holding Company (in liquidation) Phartnacia UK Limited Phartnacia United Inc Phami ac i a- P fi zer E E I G PHS Sub Inc Powderlect Research L irn ited PouderJect Therapeutics Inc PowderJect Vaccines Inc PowderMed Limited PowderMed Vaccines Inc PowderMed Inc ProRe SA Prosec (Ireland) Limited Prosec Forsakrings AB (Prosec Insurance Co Ltd) PT Capsugel Indonesia PT Pfides Pharma PT Pfizer Indonesia Quigley Coinpan) Inc Renrall LLC Rinat Neuroscience Corp Rivepar Roerig BV Roerig Produtos Farmaceuticos Lda Roerig SA Roerig Inc Roerig SA Searle amp Co Searle Argentina SRL Searle Belgium BVBA Searle Chemicals Inc Searle de Mexico SA de CV Searle GmbH Searle Holdings B V Searle Invest B V Searle Laboratorios Lda Searle LLC Searle Ltd Sefarma Sr I Sensus Drug Development Corporation Shiley International Shiley LLC Sinergis Farilia-Produtos Farmaceuticos Lda Site Realty Inc

Michigan Ireland Malaysia Hungary Poland Peru United Kingdom Singapore United Kingdom United Kingdom Philippines United Kingdom Delaware United Kingdom Delaware Delaware United Kingdom Delaware Delaware Luxembourg Ireland Sweden Indonesia Indonesia Indonesia New York Wyoming Delaware France Netherlands Portugal Chile Philippines Venezuela Delaware Argentina Belg iu in Delaware Mexico Gennany Netherlands Netherlands Portugal Nevada Bermuda Italy Delaware California California Portugal Delaware

Page 13 of15

httpllwuwsec govArchivesedgardata7800300009304 1 30800 1 360c52 04 ex2 - htm 3 I2 12008

-- ConLzrted by SEC Publisher created bjr BCL ~lrsquotxlinologies Inc lrsquoor SEC Filing

SmithKline Beechani Animal Health (SWA) (Pty) Ltd Namibia Solinor Investments SARL Luxembourg Solinor LLC Delaware Substantia (S A S ) Sugen Inc Delaware Suzhou Capsugel Ltd Swordfish Holding GmbH Germany

France


Page 14 of 15

httpwwwsec~ovArchivesedgardata7800300009304 130800 1360c52 1 04 - ex2 1 htm 32 1 DO08

-- Conered by SEC Publisher created bgt BCL lechnologies Inc for SIIC Filing Page 15 of 15

Tabor Corporation Delaware The Pfizer Incubator LLC Delaware The Kodiak Company Ltd Bermuda The Upjohn Holding Company M LLC Delaware The Upjohn Manufacturing Company LLC Delaware Thorney Company Ireland Upjohn International Holding Company Delaware U pj o h n I n t ern at i ona I I n c Michigan Upjohn Laboratorios Lda Portugal Upjohn Pharmaceuticals Limited Delaware Vaccination Services S de R L de CV Mexico Viagra Ltd United Kingdom Vicuron Pharmaceuticals Inc Delaware Vicuron Pharmaceuticals Italy Sr1 Italy Vinci Farina SA Spain Warner Lambert (UK) Limited Warner Lambert Company (M) Sdn Bhd Warner Lambert Consumer Healthcare Pty Limited Warner Lambert del Uruguay SA Warner Lambert llac Sanayi ve Ticaret Limited Sirketi Turkey

United Kingdom Malaysia Australia Uruguay

Warner Lambert Poland Spz00 Warner Lambert Pty Limited Warner Lambert Zimbabwe (Private) Limited Warner-Lambert (East Africa) Limited Warner-Lambert (Nigeria) Limited Warner-Lambert (Tanzania) Limited Warner-Lambert (Thailand) Limited Warner-Lambert Company AG Warner-Lambert Company LLC Warner-Lambert de El Salvador SA de CV Warner-Lambert de Honduras Sociedad Anonitna Warner-Lambert de Puerto Rico Inc Warner-Lambert GmbH Warner-Lambert Guatemala Sociedad Anoniina Warner-Lambert Ireland Warner-Lambert Kenya Limited Warner-Lambert Pottery Road Limited Warner-Lambert SA (Pty) Limited Warner-Lambert SA Wilcos Sweets (Pty) Limited W-L (Europe) W-L (Portugal) W-L (Spain) WL de Guatemala Sociedad Anoninia W-L LLC Yusafarm DOO

Poland Australia Zimbabwe Kenya Nigeria Tanzan i a Thailand Switzerland Delaware El Salvador Honduras Puerto Rico Germany Guatemala Ireland Kenya Ireland South Africa Delaware South Africa United Kingdom United Kingdom United Kingdom Guatemala Delaware Serbia

http ~~w~secgo~~Archivesedgardat~7800300009304 130800 1360c52 104-ex2 1 htm 32 1 ZOO8

Name of Facility

Pfizer Inr 235 East 42nd Street New lork NY 10007-5755


March 25 2008

Pliarmacia amp Upjohn Company LLC License 2 1-00 182-03

Steven Reynolds Director U S N uc I ear Reg u la t ory C om m i ss i on Division of Nuclear Material Safet) 2443 Warrenville Road STE 2 I O Lisle IL 60532-4352

7000 Portage Road Kalamazoo MI 4900 1

- Re Financial Assurance for Pharmacia amp Upjohn Company LLC (Kalainazoo MI)

Dear Mr Reynolds

1 am the chief financial officer of Pfizer Inc 235 East 42Id Street New York Ne Yorh 1001 7 a corporation This letter is in support ofthis firms use of the parent coinpan guarantee financial test to demonstrate financial assurance as specified in I O CFR Part 30

This firm guarantees through the parent company guarantee submitted to demonstrate compliance under 10 CFR Part 30 the decoinmissioning of the following facilities owned or operated bq this firm The current cost estimates or certified amounts for decommissioning so guaranteed are s h o w for each fac i 1 i ty

$17133000

I hereby certify that Pfizer Inc is currently a going concern and that it possesses p0sitiLe tangible net worth i n the amount of $23129000000

The fiscal year ofthis f i rm ends on December 3 1 The figures for the foIIo~ing items niarhed vith a11 asterisk are derived from this firms independently audited year-end fliiancial statements and footnotes for the latest completed fiscal year ended December 3 I 2007 or from the firms internal accounting records underlying such financial statement A copy of this firms most recent financial statements is enclosed

This firm is required to file a Form IO-K with the US Securities and Exchange Commission for the latest fiscal year This firm has at least one class of equity securities registered under the Securities Exchange Act of 1934

1

Alternative 2





TOTAL $ I 56833784






051407 amp 121307

051517 amp 121514

2

3

4

5

6

7

8

9

I O

1 I





$23129000000

$295 12000000

YES NO X

X


X

X




2

I




Pfizer Inc




3


















March 252008







($20498)



Tangible Net Worth

6


$23129


($99809)

$293 I2

6



L



Recitals











OR






5

Name of Facility




I







2

I O

1 1

12

13

14

16

17









3



Pfizer Inc



4





















March 25 2008












February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15








1

Alternative 2





TOTAL $ I 56833784






051407 amp 121307

051517 amp 121514

2

3

4

5

6

7

8

9

I O

1 I





$23129000000

$295 12000000

YES NO X

X


X

X




2

I




Pfizer Inc




3


















March 252008







($20498)



Tangible Net Worth

6


$23129


($99809)

$293 I2

6



L



Recitals











OR






5

Name of Facility




I







2

I O

1 1

12

13

14

16

17









3



Pfizer Inc



4





















March 25 2008












February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15


-- Converted by SEC Publisher creatccl 1 3 ~ I3CL I cchnologies Inc frsquoor S I X Filing of 15








Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15










Pfizer Inc




3


















March 252008







($20498)



Tangible Net Worth

6


$23129


($99809)

$293 I2

6



L



Recitals











OR






5

Name of Facility




I







2

I O

1 1

12

13

14

16

17









3



Pfizer Inc



4





















March 25 2008












February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15

























March 252008







($20498)



Tangible Net Worth

6


$23129


($99809)

$293 I2

6



L



Recitals











OR






5

Name of Facility




I







2

I O

1 1

12

13

14

16

17









3



Pfizer Inc



4





















March 25 2008












February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15
















March 252008







($20498)



Tangible Net Worth

6


$23129


($99809)

$293 I2

6



L



Recitals











OR






5

Name of Facility




I







2

I O

1 1

12

13

14

16

17









3



Pfizer Inc



4





















March 25 2008












February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15














($20498)



Tangible Net Worth

6


$23129


($99809)

$293 I2

6



L



Recitals











OR






5

Name of Facility




I







2

I O

1 1

12

13

14

16

17









3



Pfizer Inc



4





















March 25 2008












February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15










L



Recitals











OR






5

Name of Facility




I







2

I O

1 1

12

13

14

16

17









3



Pfizer Inc



4





















March 25 2008












February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15









OR






5

Name of Facility




I







2

I O

1 1

12

13

14

16

17









3



Pfizer Inc



4





















March 25 2008












February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15


-- ConLertcd 17) SI-ltrsquo Irsquoiit7lishcr crcatcil 12) K l lsquoI ethnologies Inc for SEC Filing of 15


Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15








I O

1 1

12

13

14

16

17









3



Pfizer Inc



4





















March 25 2008












February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15










Pfizer Inc



4





















March 25 2008












February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15




























March 25 2008












February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








of 15





Page 13 of15




France


Page 14 of 15


















March 25 2008












February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





of15




France


Page 14 of 15



















February 29 2008












February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


of 15


















February 292008



EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15


-- Conered by SEC Publisher created bgt BCL lechnologies Inc for SIIC Filing of 15







EX-2 1 12 c52 104-ex2 1 htm

Page 1 of 15

EXHIBIT 21






-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15








-




Page 2 of 15










Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15
















Page 4 of 15







C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15













C h em icals S A E

Isle of Jersey


United Kingdom

Page 5 of 15


~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15








~ -__~




Page 6 of 15




- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15










- -




Page 7 of 15





Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15











Page 8 of 15




Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15










Belgium






Egypt





Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15










Page 10 of 15








Page 12 of 15





Page 13 of15




France


Page 14 of 15














Page 12 of 15





Page 13 of15




France


Page 14 of 15











Page 13 of15




France


Page 14 of 15










France


Page 14 of 15








ptizer inc east street new york, ny · ptizer inc 235 east 42nd street new york, ny 1ool7-5755...

Documents